The InfoChemist  |  Industry & Business

Olin and Huntsman Agree to Merge, Creating a $12.5 Billion Chemical Giant

Two of the oldest names in American chemical manufacturing are becoming one company, in a deal investors greeted with a shrug rather than a rally.

The InfoChemist  |  Industry & Business News

The deal, in brief

Olin Corporation and Huntsman Corporation have agreed to combine in an all-stock merger announced June 16, 2026, pairing the world’s largest chlorine producer with one of its biggest industrial consumers. The combined company, to be renamed OlinHuntsman Corporation, will carry roughly $12.5 billion in combined 2025 sales. Olin shareholders will hold approximately 54.5 percent of the new company and Huntsman shareholders the remaining 45.5 percent.

Olin, incorporated in 1892, built its business around chlor-alkali chemistry: chlorine, caustic soda, chlorinated organics, and sodium hypochlorite, which remains its largest segment. It also carries an epoxy business acquired alongside chlor-alkali assets in its 2015 purchase of Dow’s chlorine-chemicals unit, and, less predictably for a chemical company, the ammunition maker Winchester, which contributed roughly $1.7 billion in 2025 sales. Huntsman, founded in 1982 by Jon M. Huntsman Sr. and expanded largely through acquisition since, posted $5.7 billion in 2025 sales across a broader specialty and commodity chemicals portfolio. Olin posted $6.8 billion.

The companies say the transaction will deliver more than $400 million in cost synergies, though on a timeline that runs to 2031, longer than typical for a deal this size. Investors were not immediately convinced: shares of both companies fell in the hours after the announcement, a signal worth watching as integration and synergy detail is disclosed over the coming months.

Why chlor-alkali economics matter here

The logic of pairing a major chlorine producer with a major chlorine consumer is straightforward on paper. Huntsman’s downstream chemistry relies on chlorine-derived intermediates, and vertical integration between producer and consumer can smooth the cyclical pricing swings chlor-alkali markets are known for. Caustic soda demand tracks industries like pulp and paper, alumina refining, and water treatment, while chlorine demand tracks PVC and other downstream plastics markets, meaning the combined company’s earnings will still move with construction and industrial demand even with tighter internal alignment between the two legacy businesses.

The wider consolidation wave this sits inside

Olin-Huntsman is not an isolated event. Chemical industry M&A activity ran at roughly $67 billion in deal value on a trailing-twelve-month basis through the first quarter of 2026, across 552 transactions, according to PwC’s midyear deals outlook. The character of that activity matters more than the headline figure: capital is concentrating in specialty platforms with defensible margins, coatings, advanced materials, nutrition, water treatment, rather than a broad cyclical recovery, while commodity-exposed assets, particularly in Europe, face real valuation pressure from high energy costs and Chinese capacity additions.

Elsewhere in the sector this year, Henkel agreed to acquire Dutch specialty coatings maker Stahl for €2.1 billion to expand its adhesive technologies business, and AkzoNobel rejected a €7.5 billion ($8.6 billion) bid from Nippon Paint for its decorative paints unit, choosing instead to press ahead with its own agreed merger with Axalta Coating Systems. It is the latest round in a saga that saw Nippon Paint and Sherwin-Williams jointly approach AkzoNobel with a €12.5 billion offer for the whole company earlier in the year, an approach Akzo also rejected. On the divestiture side, Ineos Enterprises completed the sale of its ultra-pure sulfur dioxide business to Ecovyst, and Lonza agreed to divest its Capsules & Health Ingredients business to Lone Star Funds for a $3 billion enterprise value, evidence that portfolio rationalization, not just outright acquisition, is a major driver of 2026 deal flow as diversified chemical companies narrow toward higher-margin segments.

The regulatory backdrop

Any deal combining the world’s largest chlorine producer with a major industrial buyer of chlorine derivatives will draw scrutiny, and the current US merger-review environment is less permissive than it was a decade ago. The FTC and DOJ’s 2023 Merger Guidelines set a more demanding analytical framework with heightened focus on competitive effects, particularly in already-concentrated segments, and chlor-alkali production, with few large-scale North American producers, is a reasonable candidate for that kind of scrutiny. Whether Olin-Huntsman clears review without conditions, or faces divestiture requirements in overlapping product lines, will be one of the more consequential regulatory tests for chemical-sector consolidation this year.

What to watch next

Three things are worth tracking as this merger moves from announcement toward its expected first-half-2027 close: whether the disclosed cost-synergy targets are enough to reverse the initial negative share-price reaction; how antitrust regulators approach the chlor-alkali overlap under the tightened 2023 guidelines; and whether the broader divergence between premium-priced specialty platforms and pressured commodity assets continues to shape which chemical companies end up as buyers, sellers, or merger partners before the year is out.

Related on The InfoChemist: Green Chemistry in 2026: What’s Changed and What Hasn’t